Witness the boxes of Wegovy created by Novo Nordisk displayed at a pharmacy in London, UK on March 8, 2024.
Photographed by Hollie Adams | Reuters
The European Union’s drug regulatory body has concluded that there is no evidence linking popular weight loss and diabetes medications like Wegovy and Ozempic to an increased risk of suicidal thoughts and self-harm, as announced on Friday.
After a thorough nine-month investigation, the European Medicines Agency found no connection between these medications, known as GLP-1s, and mental health risks. These drugs, which have surged in popularity despite their high costs and limited insurance coverage, mimic a gut hormone to reduce appetite.
The review focused on various Novo Nordisk drugs, including Wegovy and Ozempic, but did not cover Eli Lilly’s Zepbound and Mounjaro. However, it did include the active ingredient in Eli Lilly’s older diabetes treatment, Trulicity.
For more information, please refer to…
2024-04-12 11:00:50
Originally posted on www.cnbc.com